Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

The Pfizer/BioNTech bivalent COVID-19 vaccine (Original and Omicron BA.4/BA.5) has the FDA’s EUA for use in individuals 5 years and over as a single booster dose administered at least two months ...

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

How are the new vaccines different from last fall’s boosters? The updated mRNA vaccines from Moderna and Pfizer-BioNTech target the KP.2 strain, part of the Omicron lineage that began spreading last ...

Both Moderna and Pfizer-BioNTech manufacture the COVID vaccine in lower doses ... but they're not immune to the virus. "At ...

Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical development across multiple solid tumors. The analyst notes that the data ...

Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price target of $137.00. Chris Shibutani’s rating is based on ...

Goldman Sachs upgraded BioNTech (BNTX) to Buy from Neutral with a price target of $137, up from $90. The firm upgrade the shares after incorporating forecasts for BNT327, a novel immuno-oncology ...

The global peptide therapeutics market size was valued at USD 45.43 billion in 2023. It is projected to reach from USD 48.11 ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

The number of COVID cases increased last week to 146. Cases had been falling in April and May and were as low as 31 at the ...